Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Toddler diagnosed with cancer makes remarkable recovery after aggressive treatment - 2Figure out How to Explore the Infotainment Framework in the Slam 1500.
- 3Dwayne ‘the Rock’ Johnson opens up about being the 'new guy' again — and why this moment feels like a new life
- 4Material of Innovativeness: A Survey of \Releasing Your Imaginative Potential\ Online Workmanship Course
- 5Figure out How to Back Your Rooftop Substitution
- The most effective method to Amplify Profits from Gold Speculation: Systems and Tips
- Ukraine confirms defence and energy ministers at second attempt
- CDC vaccine panel votes to remove universal hepatitis B birth dose recommendation
- RFK Jr. releases new dietary guidelines with emphasis on protein, full-fat dairy
- This Luxurious Thermal Spa In Italy Is Perfect For A Relaxing Escape While Visiting Milan
- Island Travel Guide: Must-Visit Objections for 2024
- The Incomparable Advanced cameras: Which One Will Win?
- Fundamental Home Exercise center Hardware: Amplify Your Exercises
- Tech for Learning: Online Courses and Instructive Apparatuses
